About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

FDA Approves Eteplirsen For Duchenne Muscular Dystrophy

by Madhumathi Palaniappan on September 20, 2016 at 2:39 PM
Font : A-A+

FDA Approves Eteplirsen For Duchenne Muscular Dystrophy

The United States Food and Drug Administration has recently approved Eteplirsen from Sarepta Therapeutics of Cambridge, Massachusetts for treating patients with Duchenne Muscular Dystrophy(DMD).

Muscular Dystrophy is a rare genetic disorder characterized by muscle deterioriation and weakness. This disease occurs due to the absence of dystrophin protein which is essential for keeping the muscle cells intact. It usually affects boys between the age of 3 and 5.About 9000 -12000 boys in the United States were affected with Duchenne Muscular Dystrophy. These boys usually need a wheel chair during their early 20s.

Advertisement


Eteplirsen (Exondys 51) is mainly given for patients with mutation in dystrophin gene. The drug has received accelerated approval from FDA for treating life threatening conditions. Clinical trials were required to confirm the benefits of the drug. Around 12 boys with Duchenne Muscular Dystrophy were tested using eteplirsen drug. Common side effects like balance disorder and vomiting were reported by the participants.

The drug acts by a technology known as the Exon skipping, by which the functional form of dystrophin is produced. And was found to be applicable only for 13% of the patients with duchenne muscular dystrophy.
Advertisement

Dr. Janet Woodcock, Director of the F.D.A.'s Center for Drug Evaluation and Research,said that "We eagerly await learning more about the efficacy of this drug through a confirmatory clinical trial that the company must conduct after approval."

The agency has also asked Sarepta therapeutics to compare the efficacy of the drug with placebo control. And if the drug fails to answer then the agency must initiate proceedings for withdrawing the approval.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
H1N1 Influenza Prevention in Children: What Parents Need to Know
Dietary Factors Responsible for Dihydrotestosterone (DHT) Production and Hair Loss
Test Your Knowledge About Chromosomes?
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Muscular Dystrophy Genetic Testing of Diseases Dysarthria 

Most Popular on Medindia

Vent Forte (Theophylline) Sanatogen Selfie Addiction Calculator The Essence of Yoga Sinopril (2mg) (Lacidipine) Find a Hospital Blood Donation - Recipients Blood Pressure Calculator A-Z Drug Brands in India Noscaphene (Noscapine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

FDA Approves Eteplirsen For Duchenne Muscular Dystrophy Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests